Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NATALIZUMAB Cause Beta haemolytic streptococcal infection? 5 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Beta haemolytic streptococcal infection have been filed in association with NATALIZUMAB (TYRUKO). This represents 0.0% of all adverse event reports for NATALIZUMAB.

5
Reports of Beta haemolytic streptococcal infection with NATALIZUMAB
0.0%
of all NATALIZUMAB reports
0
Deaths
3
Hospitalizations

How Dangerous Is Beta haemolytic streptococcal infection From NATALIZUMAB?

Of the 5 reports, 3 (60.0%) required hospitalization.

Is Beta haemolytic streptococcal infection Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NATALIZUMAB. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does NATALIZUMAB Cause?

Multiple sclerosis relapse (6,478) Fatigue (4,456) Multiple sclerosis (4,078) Memory impairment (3,024) Malaise (2,523) Fall (2,481) Headache (2,476) Gait disturbance (2,427) Prescribed underdose (2,162) Maternal exposure during pregnancy (1,948)

What Other Drugs Cause Beta haemolytic streptococcal infection?

IBUPROFEN (61) INFLIXIMAB (58) ADALIMUMAB (53) ACETAMINOPHEN (40) ETANERCEPT (35) PREDNISOLONE (34) PREDNISONE (27) METRONIDAZOLE (26) RITUXIMAB (26) METHOTREXATE (25)

Which NATALIZUMAB Alternatives Have Lower Beta haemolytic streptococcal infection Risk?

NATALIZUMAB vs NATALIZUMAB-SZTN NATALIZUMAB vs NATAMYCIN NATALIZUMAB vs NATEGLINIDE NATALIZUMAB vs NAVITOCLAX NATALIZUMAB vs NAXITAMAB-GQGK

Related Pages

NATALIZUMAB Full Profile All Beta haemolytic streptococcal infection Reports All Drugs Causing Beta haemolytic streptococcal infection NATALIZUMAB Demographics